Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors

Figure 3

Doxorubicin-mediated growth inhibition in MPNST-derived NF02.2 cells with high ABCC1 expression. A) Relative cell content (as a percentage of untreated control cells) following 96 hours of growth in doxorubicin-containing media with and without 100 μM verapamil. Average doxorubicin EC50 1.23 μg/ml, versus 0.21 μg/ml in the presence of verapamil *p = 0.003, n = 5. B) No growth inhibition is observed with verapamil alone at concentrations 125 μM and lower. Dotted line indicates 100 μM concentration used in (A).

Back to article page